Pelage Pharma Doses First Patients in Its Phase 2 Trial

Pelage Pharmaceuticals has announced that it has dosed the first participants in its Phase 2a trial for its androgenic alopecia treatment PP405. PP405 is purported to stimulate hair follicle stem cells, triggering dormant biological processes and reinvigorating the natural hair growth cycle. This compound is said to work by targeting specific cells within the hair follicle, aiming to reawaken their ability to promote hair growth that may have become inactive over time. The trial will include 60 men and women and study its efficacy and safety.